Retatrutide (LY-3437943)
Retatrutide is a triple-agonist peptide that simultaneously acts on:
- GLP-1 receptors
- GIP receptors
- Glucagon receptors
This unique combination is central in international scientific research on:
- Energy balance
- Metabolic regulation
- Glucose homeostasis
- Incretin synergy and fat oxidation
Research Findings:
In phase-2 studies by Eli Lilly, published in The New England Journal of Medicine (2023), participants experienced an average weight reduction of 17–24% over 24–48 weeks, depending on dose and study design.
Improvements were also observed in metabolic markers, including HbA1c reductions in models of type 2 diabetes.
Further studies focus on long-term mechanisms and safety of combined incretin agonists.
Included in Each Order:
Each order contains a complete research kit:
- ✓ Retatrutide Pen – 60 mg (pre-reconstituted)
- ✓ 4× sterile 32G – 4 mm needles
- ✓ Alcohol wipes
Why Choose the Retatrutide Pen:
- ✓ Ready for immediate laboratory use
- ✓ No reconstitution required
- ✓ Consistent concentration & reproducible results
- ✓ Suitable for controlled research protocols
- ✓ Available in multiple dosages
Storage & Shipping:
- Store refrigerated immediately upon receipt according to lab guidelines
- Product delivered within 24 hours to ensure stability
- Sale and delivery limited to the Netherlands
Application & Use (Research Only):
- Developed for in-vitro research purposes
- Not intended for medical, therapeutic, or diagnostic use
- Use only within a controlled research environment
Legal Notice:
- For laboratory research only
- Not intended for human or animal consumption or injection
- Not approved as a drug or medical product
- Buyers are responsible for compliance with local laws and regulations
- Seller is not liable for improper or unauthorized use






Reviews
There are no reviews yet.